Since there are no small molecules or inhibitors known to treat NEPC, we discovered that targeting CHRM4 using Food and Drug Administration (FDA)-approved small compounds may inhibit tumor growth and NED in prostate cancer cells in vitro and in vivo. Here, CHRM4 is linked to prostate cancer.